References
1. Hull M.W., Montaner J.S.G. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011; 43 (5): 375–88. DOI: https://doi.org/10.3109/07853890.2011.572905
2. Mahlab-Guri K., Asher I., Gradstein S., Zung A., Radian-Sade S., Elbirt D., et al. Inhaled fluticasone causes iatrogenic Cushing’s syndrome in patients treated with ritonavir. J Asthma. 2011; 48 (8): 860–3. DOI: https://doi.org/10.3109/02770903.2011.606580
3. Epperla N., McKiernan F. Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. Springerplus. 2015; 4 (1): 455. DOI: https://doi.org/10.1186/s40064-015-1218-x
4. Saberi P., Phengrasamy T., Nguyen D.P. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013; 14 (9): 519–29. DOI: https://doi.org/10.1111/hiv.12039
5. Pollett S., Graves B., Richards B., MacLeod C. Avascular necrosis in a HIV patient receiving ritonavir and inhaled fluticasone. Int J STD AIDS. 2014; 25 (6): 458–60. DOI: https://doi.org/10.1177/0956462413513747
6. Alidoost M., Conte G.A., Agarwal K., Carson M.P., Lann D., Marchesani D. Iatrogenic Cushing’s syndrome following intra-articular triamcinolone injection in an HIV-infected patient on cobicistat presenting as a pulmonary embolism: case report and literature review. Int Med Case Rep J. 2020; 13: 229–35. DOI: https://doi.org/10.2147/IMCRJ.S254461
7. Dubrocq G., Estrada A., Kelly S., Rakhmanina N. Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy. Endocrinol Diabetes Metab Case Rep. 2017; 2017: 17-0076. DOI: https://doi.org/10.1530/EDM-17-0076
8. Song Y., Schroeder J.R., Bush L.M. Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. J Int Assoc Provid AIDS Care. 2014; 13 (6): 511–4. DOI: https://doi.org/10.1177/2325957413488187
9. Yombi J.C., Maiter D., Belkhir L., Nzeusseu A., Vandercam B. Iatrogenic Cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol, 2008; 27 (suppl 2): 79–82. DOI: https://doi.org/10.1007/s10067-008-1022-x
10. Alikhani A., Morin H., Matte S., Alikhani P, Tremblay C., Durand M. Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal. BMC Infect Dis. 2019; 19 (1): 820. DOI: https://doi.org/10.1186/s12879-019-4446-9
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, 2019.
12. Bons J., Moreau L., Lefebvre H. Adrenal disorders in human immunodeficiency virus (HIV) infected patients. Ann Endocrinol (Paris). 2013; 74 (5–6): 508–14. DOI: https://doi.org/10.1016/j.ando.2013.09.002
13. Sukhumthammarat W., Putthapiban P., Sriphrapradang C. Local injection of triamcinolone acetonide: a forgotten aetiology of Cushing’s syndrome. J Clin Diagn Res. 2017; 11 (6): OR 01–2. DOI: https://doi.org/10.7860/JCDR/2017/27238.10091
14. Ramanathan R., Pau A.K., Busse K.H., Zemskova M., Nieman L., Kwan R., et al. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. Clin Infect Dis. 2008; 47 (12): e97–9. DOI: https://doi.org/10.1086/593314
15. Jakeman B., Conklin J., Bouchonville M., Thornton K. Iatrogenic Cushing’s syndrome after triamcinolone plus ritonavir-boosted atazanavir. J Am Pharm Assoc. (2003). 2015; 55 (2): 193–7. DOI: https://doi.org/10.1331/JAPhA.2015.14114